Neuroblastoma (NB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Neuroblastoma, a malignant tumor originating from neural crest cells responsible for the sympathetic nervous system, predominantly affects children. Its occurrence may be sporadic or inherited in the germline, with familial cases often linked to mutations in ALK or PHOX2B genes. Some familial cases exhibit autosomal dominant inheritance. Additionally, common transforming mutations involve polymorphisms in genes like BARD1, LIN28B, or FLJ22536. Genetic anomalies, including MYCN amplification and chromosomal abnormalities, significantly impact prognosis. Diagnosis relies on elevated urinary catecholamine metabolites and imaging techniques like ultrasound, brain scan, or MRI. MIBG scintigraphy and medullary analysis aid in metastasis detection. Differential diagnosis includes nephroblastoma, while bone pain and limp may be mistaken for hip synovitis, and peri-orbital hematomas are misinterpreted as maltreatment signs. Treatment modalities encompass surgery, chemotherapy, radiotherapy, and immunotherapy. However, the prognosis is notably poor for around 60% of children over one year with metastatic disease, despite intensive treatment efforts.

·       Survival rates vary, ranging from 95% for localized tumors to 30% for metastatic cases, accounting for about 10% of solid tumors in infants and children under 15, with an annual incidence of approximately 1/70,000 in this age group.

 

Thelansis’s “Neuroblastoma (NB) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroblastoma (NB) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Neuroblastoma (NB) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neuroblastoma (NB) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Neuroblastoma (NB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Neuroblastoma (NB), Neuroblastoma (NB) market outlook, Neuroblastoma (NB) competitive landscape, Neuroblastoma (NB) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033